Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;17(9):533-542.
doi: 10.1038/s41575-020-0332-6. Epub 2020 Jul 23.

Progress towards elimination goals for viral hepatitis

Andrea L Cox  1 , Manal H El-Sayed  2 , Jia-Horng Kao  3   4 , Jeffrey V Lazarus  5 , Maud Lemoine  6 , Anna S Lok  7 , Fabien Zoulim  8   9   10
Affiliations

Progress towards elimination goals for viral hepatitis

Andrea L Cox et al. Nat Rev Gastroenterol Hepatol. 2020 Sep.

Abstract

The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. In 2016, the 194 Member States of the World Health Organization committed to eliminating viral hepatitis as a public health threat by 2030, with a particular focus on hepatitis B virus and hepatitis C virus infection. With only 10 years to go until the 2030 deadline is reached, and although much progress has been made towards elimination, there are still some important gaps in terms of policy and progress. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field for their opinions on whether elimination of viral hepatitis by 2030 is feasible, what the key areas of progress are and what the focus for the next 10 years and beyond should be for viral hepatitis elimination.

PubMed Disclaimer

Conflict of interest statement

M.H.E.-S. has received an educational grant from Gilead. J.-H.K. declares that he has acted as a consultant for Arbutus, Gilead Sciences and Roche, and appeared on speaker’s bureau for Bristol-Myers Squibb, Gilead Sciences, Fujirebio, Merck Sharp & Dohme and Roche. J.V.L. reports grants and personal fees from AbbVie, Gilead Sciences and MSD, and personal fees from CEPHEID, GlaxoSmithKline, Intercept and Janssen, outside of the submitted work. M.L. has received funding and fees from Gilead and Viiv Health care. A.S.L. acknowledges research grants (to the University) from Assembly, Bristol-Myers Squibb, Gilead, and TARGET, and has served on advisory boards or as a consultant for Gilead, GlaxoSmithKline, Huahui, Spring Bank and TARGET. F.Z. has research contracts through INSERM with Evotec and Roche. He has also acted as an advisor or consultant for Assembly, Aligos, Evotec, Galapagos, Gilead, GlaxoSmithKline, Myr Pharma, Roche Molecular Systems, Transgene and Vir Bio. A.L.C. declares no competing interests.

References

    1. Thomas DL. Global elimination of chronic hepatitis. N. Engl. J. Med. 2019;380:2041–2050. - PubMed
    1. Stanaway JD, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–1088. - PMC - PubMed
    1. Liu J, Liang W, Jinga W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull. World Health Organ. 2019;97:230–238. - PMC - PubMed
    1. McCulloch F, Romero N, MacLachlan J, Allard N, Cowie B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology. 2020;71:1170–1181. - PMC - PubMed
    1. Razavi-Shearer D, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 2018;3:383–403. - PubMed

Publication types